摘要
目的:观察雷贝拉唑治疗幽门螺杆菌(Hp)阴性胃溃疡的临床疗效与安全性。方法:收集经胃镜检查证实患Hp阴性胃溃疡的患者并随机分成治疗组与对照组,治疗组50例,对照组50例,治疗组服用雷贝拉唑肠溶胶囊1粒(20 mg/粒),2次/d,对照组服用奥美拉唑肠溶胶囊1粒(20 mg/粒),2次/d,疗程6周。结果:胃溃疡的治愈率两组分别为93.70%与94%,差异无统计学意义(P>0.05)。治疗期间患者对两组药物均有较好的耐受性。结论:雷贝拉唑治疗Hp阴性胃溃疡有较高的治愈率与症状改善率,疗效与奥美拉唑相当,是一种安全、有效的新一代质子泵抑制剂。
Objectlve To observe the effect and satety ot applying Rabeprazole m treatment ox acuve gasmo ulcer wlmout tap lmec tion. Method 100 patients with gastric ulcer without Hp infection were divided randomly into trail group and control group,50 patients in trail group received Rabeprazole 40 mg qd for 6 weeks, while 50 patients in control group received Omeprazole 40 mg qd for 6 weeks. Results After 6 weeks＇ treatment, gastric ulcer withfout Hp infection healing rates were 94% in the Rabeprazole group and 92% in the Omeprazole group, there was no significant statistical difference between the Rabeprazole group and the Omeprazole group（ P 〉 0. 05）, and both drugs were well tolerated. Conclusion In this study, healing rate of Rabeprazole is equal to Omeprazole in gastric ulcer without Hp infection, Rabeprazole is an efffective and safe drug for the treatment of active gastric ulcer without Hp infection.
出处
《吉林医学》
CAS
2013年第28期5793-5795,共3页
Jilin Medical Journal
关键词
胃溃疡
HP阴性
雷贝拉唑
奥美拉唑
Gastric ulcer
Without Hp infection
Rabeprazole
Omeprazole
